🚀 Thrilled to announce a $150 million Series C financing! We are grateful to co-leads Frazier Life Sciences and Lightspeed Venture Partners, and all our new and existing investors. This funding will significantly advance our precision oncology pipeline, including key programs STX-478, STX-721 and STX-241. Discover how this supports our mission to push the boundaries of precision oncology https://bit.ly/4d36l6U
Scorpion Therapeutics
Biotechnology Research
Precision Oncology 2.0: Broadening the reach and impact of precision medicine
About us
Scorpion Therapeutics was founded to expand the reach of precision medicine to more people with cancer. The company is integrating cutting-edge technologies across target discovery, medicinal chemistry, and translational medicine to deliver Precision Oncology 2.0, a pipeline of targeted small-molecule drugs that overcome the limitations of existing treatments. Scorpion’s experienced leadership team is executing a fit-to-purpose model to efficiently unlock the next generation of precision oncology. For more information, visit scorpiontx.com.
- Website
-
http://www.scorpiontx.com
External link for Scorpion Therapeutics
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Type
- Privately Held
- Founded
- 2020
Employees at Scorpion Therapeutics
Updates
-
Scorpion Therapeutics reposted this
This week, we celebrated a special milestone - our company anniversary. It's been four years of hard work and dedication, and we’re proud of our achievements that include: 1. Advancing three compounds into development 2. Building a fully-integrated chemistry discovery engine 3. Growing our Scorpion teams in Boston and South San Francisco 4. Presenting a Trial-In-Progress at SABCS alongside Dr. Alberto Montero about our ongoing Phase 1/2 clinical study of STX-478 Here’s to many years ahead of working to deliver transformative medicines to patients!
-
It's an exciting day for the future of drug discovery in cancer. Scorpion team members alongside Co-Founder Liron Bar-Peled and scientists at Mass General Brigham authored a new study published in Cell, which looked to uncover which proteins may be druggable across cancer. These findings further attest to our commitment to developing the next generation of targeted cancer therapies and transforming the lives of patients. Read more about the study here: https://lnkd.in/emW-cUDz
-
This week, we celebrated a special milestone - our company anniversary. It's been four years of hard work and dedication, and we’re proud of our achievements that include: 1. Advancing three compounds into development 2. Building a fully-integrated chemistry discovery engine 3. Growing our Scorpion teams in Boston and South San Francisco 4. Presenting a Trial-In-Progress at SABCS alongside Dr. Alberto Montero about our ongoing Phase 1/2 clinical study of STX-478 Here’s to many years ahead of working to deliver transformative medicines to patients!
-
This International Women’s Day we are pleased to #inspireinclusion by supporting the important work Women's Lunch Place and Dress for Success Boston are doing to uplift women in our community. Their dedication to empowering women is a powerful force for positive change. #InspireInclusion #internationalwomensday Check out a picture from our recent volunteer event with Women's Lunch Place.
-
Today, we express our profound gratitude to the women of Scorpion for their commitment to transforming the lives of cancer patients. Your contributions are vital, your talent is immeasurable, and your dedication is inspiring. Scorpion is committed to #InspireInclusion and foster a work environment where all feel a sense of belonging. #InternationalWomensDay
-
Happy #EmployeeAppreciationDay! Today, we celebrate our team at Scorpion for their hard work and dedication to developing the next generation of cancer therapies. Thank you for all you do for Scorpion and for patients!
-
We are proud to see STX-478 on this illustrious list and in great company!
Top 12 Most Popular Drug Hunter Case Studies of 2023 | https://lnkd.in/eKMeqqqK 2023 was an incredible year in drug discovery, with many remarkable case studies on challenging targets like KRAS, programs employing emerging modalities like degraders or oral macrocyclic peptides, and compounds with fascinating properties like allostery and mutant-selectivity. Check out the top 12 most popular case studies published in 2023 here: Full list: https://lnkd.in/eKMeqqqK
Top 12 Most Popular Drug Hunter Case Studies of 2023
-
Scorpion Therapeutics reposted this
I'm super excited to announce that I have joined Scorpion Therapeutics as Chief Medical Officer. Looking forward to working with Adam Friedman, MD, PhD, the leadership team, founders (Keith Flaherty, Gaddy Getz, Liron Bar-Peled), board members (Jeff Albers, Jean-Francois Formela, Otello Stampacchia, Arjun Goyal, M.D., Oleg Nodelman, Saurabh Saha MD PhD and Shelley Chu) and the entire team at Scorpion. I have been impressed with the level of science, robust clinical and research pipeline and the people. I'm looking forward to working with the team to help continue its success! https://lnkd.in/gnQwz_p7
Scorpion Therapeutics Appoints Adam Friedman, M.D., Ph.D., as Chief Executive Officer and Expands Leadership Team - Scorpion Therapeutics
scorpiontx.com
-
As we kick off 2024, we want to share some exciting news about current and new members of our executive leadership team. Adam Friedman, MD, PhD has been appointed as CEO of Scorpion Therapeutics, a move that underscores his many contributions from the company’s inception and sets us up well for our current trajectory of growth. We’re also pleased to announce that accomplished industry veteran, Jeff Albers, has been named Executive Chair of our Board of Directors. Mark Chao, a leading expert in clinical development, has joined Scorpion as its Chief Medical Offer and Erica Jackson has been appointed as our first Chief Discovery Officer. Please join us in extending a big congratulations to Adam, Jeff, Mark and Erica! Learn more: https://bit.ly/3RKu7LK #PrecisionOncology